Stock Track | Hims & Hers Health Soars 11.14% Intraday on FDA Peptide Regulation Easing and Novo Nordisk Partnership

Stock Track
Apr 17

Hims & Hers Health Inc. (HIMS) experienced a significant intraday surge of 11.14% on Thursday, extending gains from the previous session. The telehealth company's stock has been rallying strongly following major positive developments.

The sharp rise was primarily driven by an announcement from U.S. Health and Human Services Secretary Robert F. Kennedy Jr., who stated that the government would move to loosen regulations for 12 peptides. The Food and Drug Administration plans to convene an expert panel in July to discuss whether compounding pharmacies can produce these popular peptide substances, which could expand regulated access to peptide-based treatments.

Additionally, Hims & Hers has entered into a partnership with pharmaceutical giant Novo Nordisk to sell weight-loss drugs on its platform. This regulatory pivot and commercial partnership are seen as significant growth catalysts for the company, which had previously indicated plans to enter the peptide business and acquired a California-based manufacturing facility last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10